Important Due Date Reminders: Kessler Topaz Meltzer & Check, LLP Cassava Sciences, Inc. Provides Investor Reminders In Securities Fraud Class Action | State

0

Radnor, Pennsylvania, 10 October 2021 / PRNewswire / -Kessler Topaz Meltzer & Check, law firm LLP Cassava Sciences, Inc. (NASDAQ: SAVA) (“Cassava”) has warned investors that a securities fraud proceeding has been filed on behalf of the ‘Buyer. Or acquired Cassava Titles Between September 14, 2020 When August 27, 2021, Full (“class period”).

Deadline reminder: investor who bought or acquired cassava securities During the class Later October 26, 2021Demands that you be appointed as the lead representative of the class plaintiffs. For more information or to find out how to participate in this procedure, please contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq. (484) 270-1453; (844) 887-9500 free by email [email protected]; Also Click here..

Cassava is a clinical biotechnology company. Its main therapeutic candidate is called Simphyllum (formerly PTI-125), which was developed for the treatment of Alzheimer’s disease. Simphyllum targets a modified form of a protein called filamin A (“FLNA”) in the Alzheimer’s disease brain that returns it to its original healthy conformation and thereby neutralizes the altered downstream toxic effects of FLNA. It is said that.

The truth about Simphyllum began to come out after the deal was struck August 24, 2021, the United States Food and Drug Administration (“FDA”) has received a so-called civic petition to initiate administrative action to “suspend two ongoing trials of the drug Simufilam pending a thorough audit by the FDA.” When is disclosed. “” As detailed in the citizens’ petition, “”[i]Information available to the complainant. .. .. This raises serious concerns about the quality and integrity of the laboratory studies surrounding this drug candidate and supports its claims of efficacy. “

to 25 August 2021Before the market opened, Cassava responded to the public plea, claiming that the claim to scientific integrity was false and misleading. In particular, Cassava said the clinical data was reanalyzed by Citizen Petition to show that Simphyllum was effective, according to independent company Quantaix Corp. Claimed to have been generated by (“Quanterix”), suggesting that the reanalysis is valid.

to August 27, 2021Before the market opened, Quanterix issued a statement denying Cassava’s claims, stating that it “had not interpreted the test results or prepared the data” announced by Cassava. On the same day, Cassava responded to a statement from Quanterix by saying “Quanterix”.[s] The sole responsibility of this clinical trial was to perform sample testing, specifically to measure the level of p-tau in plasma samples taken from subjects. In response to this news, the Cassava share price fell. $ 12.51, Or ends at 17.6% $ 58.34 Per share August 27, 2021..

The complaint alleges that the Respondent failed to disclose to investors across the group: (1) The data that form the basis of basic research on cassava product candidates has been manipulated. (2) Experiments using postmortem human brain tissue frozen for nearly 10 years violated basic understanding of neurobiology. (3) Biomarker analysis of patients treated with simphyllum was designed to conclude that simphyllum was effective. (4) Quanterix, an independent company, did not interpret test results or create data tables for the analysis of biomarkers from patients treated with Simphyllum. (5) Due to the above, it was reasonably possible that cassava would be subject to regulatory review as part of the development of Simphyllum. (6) As a result of the foregoing, the Respondent’s affirmative statement regarding Cassava’s business, operations and prospects was significantly misleading and / or lacking reasonable grounds.

Cassava Investors Later October 26, 2021You can request to be appointed as the lead representative of the Class Complainants through Kessler Topaz Meltzer & Check, LLP or any other attorney, or you may choose to leave the Class Member away and do nothing. The head of the claimant is the representative party acting on behalf of all class members in the conduct of the proceedings. To be appointed as the lead plaintiff, the court must determine that the claims of one class member are typical of the claims of other class members and that the class members correctly represent the class. The possibility of sharing the recovery is not affected by the decision to act as the principal applicant.

Kessler Topaz Meltzer & Check, LLP, will pursue class actions in state and federal courts nationwide, including securities fraud, breach of trustee liability, and other violations of state and federal law. Kessler Topaz Meltzer & Check, LLP, is the driving force behind corporate governance reform and has raised billions of dollars on behalf of institutional and individual investors. united states of america And all over the world. The company represents investors, consumers and whistleblowers (private sector who report fraud against the government and share the clawback of the government dollar). The proceedings in this proceeding were not filed by Kessler Topaz Meltzer & Check, LLP. For more information on Kessler Topaz Meltzer & Check, LLP, please visit: www.ktmc.com.

Kessler Topaz Meltzer & Check, LLP

(844) 887-9500 (toll free)

Source Kessler Topaz Meltzer & Check, LLP

Important Due Date Reminders: Kessler Topaz Meltzer & Check, LLP Cassava Sciences, Inc. Provides Investor Reminders In Securities Fraud Class Action | State

Source Link Important Deadline Reminders: Kessler Topaz Meltzer & Check, LLP Cassava Sciences, Inc. Provides Investor Reminders of Securities Fraud Class Action | State


Source link

Leave A Reply

Your email address will not be published.